Sareum is an experienced and specialist Structure-based Drug Discovery company. We accelerate and improve the productivity of both our in-house and our partners' discovery research using our proprietary approaches.

Sareum has a highly experienced team with a track record of delivering high quality results for pharmaceutical and biotechnology clients.

Sareum is developing a robust pipeline of novel cancer drug candidates for partnering with pharmaceutical companies. We generate revenues to support this pipeline through the provision of our specialist discovery research services.

Sareum delivers results through the entire drug discovery value chain, from gene through to valuable preclinical candidate. We carry out complete structure-based discovery programmes for creating novel pre-clinical candidates as well as specific tailored projects to resolve clients' issues in gene to structure, structure to lead, and/or lead to candidate activities.

Sareum creates novel IP and highly valuable clinical candidates for our clients across a range of therapeutic areas. We are very flexible in our approach to how we structure our partnerships and can engage in fee-for-service, out-source research, technology transfer or joint research programmes.


http://www.sareum.co.uk/

Link to news http://www.advfn.com/p.php?pid=news&ref=803&epic=SAR&cb=1152289822

Hi Moenyplus,

What did you think of the inaugural report on Lemming Investor.com? I noted the t1ps stable tipped SAR today as 'speculative buy.'

Hi E. Interesting enough for me to buy in yesterday and add a few today. I'm holding on with Erx but feel there's more reward here.